Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 266

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Open access
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N.J., Bossert, M., Bozgan, A.-M., Charpentier, A., Roux, M.-F., Contreras, R., Mazurier, I., Dussert, P., Gendrin, V., Conrozier, T. · 2020 · Médecine et Maladies Infectieuses

Abstract

Introduction No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. Method We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions. Results Patients with TCZ (n = 20) had a higher Charlson comorbidity index (5.3 [±2.4] vs 3.4 [±2.6], P = 0.014), presented with more severe forms (higher level of oxygen therapy at 13 L/min vs 6 L/min, P < 0.001), and had poorer biological findings (severe lymphopenia: 676/mm3 vs 914/mm3, P = 0.037 and higher CRP level: 158 mg/L vs 105 mg/L, P = 0.017) than patients without TCZ (n = 25). However, death and/or ICU admissions were higher in patients without TCZ than in the TCZ group (72% vs 25%, P = 0.002). Conclusion Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.medmal.2020.05.001

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 266

Metadata

Authors
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., Bozgan, A.-M., Charpentier, A., Roux, M.-F., Contreras, R., Mazurier, I., Dussert, P., Gendrin, V., & Conrozier, T.
Venue
Médecine et Maladies Infectieuses
Publisher
Elsevier BV
Published
2020-08
Volume
50
Issue
5
Pages
397-400
ISSN
0399-077X (ISSN-L)
OpenAlex
W3021343000
Cited by
266
References
19
FWCI
7.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. https://app.cochat.ai/papers/10.1016/j.medmal.2020.05.001
The paper
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., Bozgan, A.-M., Charpentier, A., Roux, M.-F., Contreras, R., Mazurier, I., Dussert, P., Gendrin, V., & Conrozier, T. (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Médecine et Maladies Infectieuses. https://doi.org/10.1016/j.medmal.2020.05.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.